Back to search results

Research On Nicotinamide Riboside Supplement Support in MDS (ROSS Trial)

Abroad (travel likely)RecruitingPHASE2

Conditions

Clonal Cytopenia of Undetermined Significance · Myelodysplastic Syndrome

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University of Colorado Hospital, Aurora, Colorado, United States

    Contact: Study coordinator (Derek Schatz) · DEREK.SCHATZ@CUANSCHUTZ.EDU · (720) 848-0628
    Contact: Principal Investigator (Maria Amaya, PhD MD)
    Matthew Angelos, MD (Sub-investigator)
    Steven Bair, MD (Sub-investigator)
    Cassandra Duarte, MD (Sub-investigator)
    Jonathan Gutman, MD (Sub-investigator)
    Bradley Haverkos, MD (Sub-investigator)
    Manali Kamdar, MD (Sub-investigator)
    Andrew Kent, MD (Sub-investigator)
    Ajay Major, MD (Sub-investigator)
    Christine McMahon, MD (Sub-investigator)
    Jorge Monge-Urrea, MD (Sub-investigator)
    Daniel Pollyea, MD (Sub-investigator)
    Daniel Sherbenou, MD (Sub-investigator)
Study leads

  • Maria Amaya, PhD MD

    Principal Investigator

    University of Colorado, Denver

View source on ClinicalTrials.gov(opens in a new tab)